Antidepressant-drug interactions are potentially but rarely clinically significant

Neuropsychopharmacology

Volumn 31, Issue 8, 2006, Pages 1594-1604

  DeVane, C Lindsay ^a  

^a MEDICAL UNIVERSITY OF SOUTH CAROLINA   (United States)

Author keywords

Drug interactions; Drug transporters; P glycoprotein; P450; Pharmacogenetics

Indexed keywords

ALPRAZOLAM; ANTIDEPRESSANT AGENT; ANTIFUNGAL AGENT; CIMETIDINE; CISAPRIDE; CITALOPRAM; DESIPRAMINE; DIAZEPAM; FLUOXETINE; FLUVOXAMINE; HALOPERIDOL; LITHIUM; MESORIDAZINE; MIRTAZAPINE; NEFAZODONE; NITRIC ACID DERIVATIVE; NORFLUOXETINE; NORTRIPTYLINE; PAROXETINE; PIMOZIDE; SEROTONIN UPTAKE INHIBITOR; SERTRALINE; SILDENAFIL; TERFENADINE; THIAZIDE DIURETIC AGENT; THIORIDAZINE; TRICYCLIC ANTIDEPRESSANT AGENT; UNINDEXED DRUG; VENLAFAXINE; ZIPRASIDONE;

AREA UNDER THE CURVE; CLINICAL PRACTICE; DEPRESSION; DRUG EFFICACY; DRUG ELIMINATION; DRUG FATALITY; DRUG INDUSTRY; DRUG METABOLISM; DRUG POTENCY; DRUG SAFETY; DRUG TOLERABILITY; ENZYME INHIBITION; EXTRAPYRAMIDAL SYMPTOM; FOOD AND DRUG ADMINISTRATION; GENOTYPE; HUMAN; IC 50; IN VITRO STUDY; IN VIVO STUDY; MORBIDITY; POSTMARKETING SURVEILLANCE; PREDICTION; PREVALENCE; PRIORITY JOURNAL; REVIEW; STATISTICAL SIGNIFICANCE; TORSADE DES POINTES;

ANIMALS; ANTIDEPRESSIVE AGENTS; CYTOCHROME P-450 CYP2D6; DRUG INTERACTIONS; ENZYME INHIBITORS; HUMANS;

EID: 33746299419     PISSN: 0893133X     EISSN: None     Source Type: Journal    
DOI: 10.1038/sj.npp.1301069     Document Type: Review

References (161)

1. Anderson IM (1998). SSRIs versus tricyclic antidepressants in depressed inpatients: a meta-analysis of efficacy and tolerability. Depress Anxiety 7(Suppl 1): 11-17.
2. Alderman J, Preskorn SH, Greenblatt DJ, Harrison W, Penenberg D, Allison J et al (1997). Desipramine pharmacokinetics when coadministered with paroxetine or sertraline in extensive metabolizers. J Clin Psychopharmacol 17: 284-291.
3. Alfaro CL (2001). Emerging role of drug interaction studies in drug development: the good, the bad, and the unknown. Psychopharm Bull 35: 80-93.
4. Alfaro CL, Lam F, Simpson J, Ereshefsky L (2000). CYP2D6 inhibition by fluoxetine, paroxetine, sertraline, and venlafaxine in a crossover study: intraindividual variability and plasma concentration correlations. J Clin Pharmacol 40: 58-66.
5. Alfaro CL, Lam YWF, Simpson J, Ereshefsky LE (1999). CYP2D6 status of extensive metabolizers after multiple-dose fluoxetine, fluvoxamine, paroxetine or sertraline. J Clin Psychopharmacol 19: 155-163.
6. Alván G, Bechtel P, Iselium L, Gundert-Remy U (1999). Hydroxylation polymorphisms of debrisoquine and mephenytoin in European populations. Eur J Clin Pharmacol 39: 533-537.
7. American Psychiatric Association (2000). Practice guidelines for the treatment of patients with major depressive disorder (revision). Am J Psychiatry 57(4 Suppl): 1-45.
8. Aranow RB, Hudson JI, Pope HG, Grady TA, Laage TA, Bell IR et al (1989). Elevated antidepressant plasma levels after addition of fluoxetine. Am J Psychiatry 146: 911-913.
9. Azaz-Livshits T, Levy M, Sadan B, Shalit M, Geisslinger G, Brune K (1998). Computerized surveillance of adverse drug reactions in hospital: pilot study. Br J Clin Pharmacol 45: 309-314.
10. Balant-Gorgia AE, Ries C, Balant LP (1996). Metabolic interaction between fluoxetine and clomipramine: a case report. Pharmacopsychiat 29: 38-41.
11. Ball SE, Ahern D, Scatina J, Dao J (1997). Venlafaxine: in vitro inhibition of CYP2D6 dependent imipramine and desipramine metabolism; comparative studies with selected SSRIs and effects on human hepatic CYP3A4, CYP2C9 and CYP1A2. Br J Clin Pharmacol 43: 619-626.
12. Barbhaiya RH, Shukla UA, Kroboth PD, Greene DS (1995). Coadministration of nefazodone and benzodiazepines: II. A pharmacokinetic interaction study with triazolam. J Clin Psychopharmacol 15: 320-326.
13. Belpaire FM, Wijnant P, Temmerman A, Rasmussen BB, Brøsen K (1998). The oxidative metabolism of metoprolol in human liver microsomes: inhibition by the selective serotonin reuptake inhibitors. Eur J Clin Pharmacol 54: 261-264.
14. Benet LZ, Hoener B (2002). Changes in plasma protein binding have little clinical relevance. Clin Pharmacol Ther 71: 115-121.
15. Berecz R, de la Rubia A, Dorado P, Fernandez-Salguero P, Dahl M-L, Llerena A (2003). Thioridazine steady-state plasma concentrations are influenced by tobacco smoking and CYP2D6, but not by the CYP2C9 genotype. Eur J Clin Pharmacol 59: 45-50.
16. Bergk V, Gasse C, Rothenbacher D, Loew M, Brenner H, Haefeli WE (2004). Drug interactions in primary care: impact of a new algorithm on risk determination. Clin Pharmacol Ther 76: 85-96.
17. Bergstrom RF, Goldberg MJ, Cerimele BJ, Hatcher BL (1997). Assessment of the potential for a pharmacokinetic interaction between fluoxetine and terfenadine. Clini Pharmacol Ther 62: 643-651.
18. Bertelsen KM, Venkatakrishnan K, von Moltke LL, Obach RS, Greenblatt DJ (2003). Apparent mechanism-based inhibition of human CYP2D6 in vitro by paroxetine: comparison with fluoxetine and quinidine. Drug Metab Dispos 31: 289-293.
19. Bertilsson L, Eichelbaum M, Mellstrom B, Sawe J, Scholtz H-U, Sjoqvist F (1980). Nortritpyline and antipyrine clearance in relation to debrisoquine hydroxylation in man. Life Sci 27: 1673-1677.
20. Bertz RJ, Granneman GR (1997). Use of in vitro and in vivo data to estimate the likelihood of metabolic pharmacokinetic interactions. Clin Pharmacokinet 32: 210-258.
21. Bjornsson TD, Callaghan JT, Einolf HJ, Fischer V, Gan L, Grimm S et al (2003). The conduct of in vitro and in vivo drug-drug interaction studies: a pharmaceutical research and manufacturers of America (PhRMA) perspective. Drug Metab Dispos 31: 815-832.
22. Blanchard N, Richert L, Coassolo P, Lave T (2004). Qualitative and quantitative assessment of drug-drug interaction potential in man, based on Ki, IC50 and inhibitor concentration. Curr Drug Metab 5: 147-156.
23. Brøsen K, Skjelbo E, Rasmussen BB, Poulsen HE, Loft S (1993). Fluvoxamine is a potent inhibitor of cytochrome P4501A2. Biochem Pharmacol 45: 1211-1214.
24. Burke MJ, Carmichael CA, Harvey A, Preskorn SH (1996). The prevalence of polypharmacy as a potential risk for drug interactions in the outpatient treatment of major depression and the inpatient treatment of schizophrenia. Poster presented at the 36th Annual NCDEU Meeting, Boca Raton, Florida, May 28-31.
25. Busby Jr WF, Ackermann JM, Crespi CL (1999). Effect of methanol, ethanol, dimethyl sulfoxide, and acetonitrile on in vitro activities of cDNA-expressed human cytochromes P-450. Drug Metab Dispos 27: 246-249.
26. Carlile DJ, Hakooz N, Bayliss KM, Houston JB (1999). Microsomal prediction of in vivo clearance of CYP2C9 substrates in humans. Br J Clin Pharmacol 47: 625-635.
27. Chauret N, Gauthier A, Nicoll-Briffith DA (1998). Effect of common organic solvents on in vitro cytochrome P450-mediated meteabolic activities in human liver microsomes. Drug Metab Dispos 26: 1-4.
28. Clary C, Mandos LA, Schweizer E (1990). Results of a brief survey on the prescribing practices for monoamine oxidase inhibitor antidepressants. J Clin Psychiatry 51: 226-231.
29. Crane JK, Shih HT (1993). Syncope and cardiac arrhythmia due to an interaction between itraconazole and terfenadine. Am J Med 95: 445-446.
30. Crewe HK, Lennard MS, Tucker GT, Woods FR, Haddock RE (1992). The effect of selective serotonin re-uptake inhibitors on cytochrome P4502D6 activity in human liver microsomes. Br J Clin Pharmacol 34: 262-265.
31. Dahl M-L, Voortman G, Aim C, Elwin CE, Delbressine L, Vos R et al (1997). In vitro and in vivo studies on the disposition of mirtazapine in humans. Clin Drug Ivest 13: 37-46.
32. Daniel DG, Randolph C, Jaskiw G, Handel S, Williams T, Abi-Dargham A et al (1994). Coadministration of fluvoxamine increases serum concentrations of haloperidol. J Clin Psychopharmacol 14: 340-343.
33. Danish University Antidepressant Group (1990). Paroxetine: a selective serotonin reuptake inhibitor showing better tolerance, but weaker antidepressant effect than clomipramine in a controlled multi-center study. J Affect Disord 18: 289-299.
34. Davies SJC, Eayrs S, Pratt P, Lennard MS (2004). Potential for drug interactions involving cytochromes P450 2D6 and 3A4 on general adult psychiatric and functional elderly psychiatric wards. Br J Clin Pharmacol 57: 464-472.
35. DeVane CL (1998a). Clinical implications of dose-dependent cytochrome P-450 drug interactions with antidepressants. Hum Psychopharmacol 13: 329-336.
36. DeVane CL (2002). Clinical significance of drug plasma protein binding and binding displacement drug interactions. Psychopharmacol Bull 36: 5-21.
37. DeVane CL, Markowitz JS, Hardesty SJ, Mundy S, Gill HS (1997). Fluvoxamine-induced theophylline toxicity. Letter. Am J Psychiarty 154: 1317-1318.
38. DeVane CL, Markowitz JS, Liston HL, Risch SC (2001). Charleston antidepressant drug interactions surveillance program (CA-DISP). Psychopharmacol Bull 35: 50-61.
39. Eagling VA, Tjia JF, Back DJ (1998). Differential selectivity of cytochrome P450 inhibitors against probe substrates in human and rat liver microsomes. Br J Clin Pharmacol 45: 107-114.
40. Edwards JG, Inman WHW, Wilton L, Pearce GL (1994). Prescription-event monitoring of 10,401 patients treated with fluvoxamine. Br J Psychiatry 164: 387-395.
41. Eichelbaum M, Bertilsson L, Sawe J, Zekorn C (1982). Polymorphic oxidation of sparteine and debrisoquine: related pharmacogenetic entities. Clin Pharmacol Ther 31: 184-186.
42. Ekins S, Ring BJ, Grace J, McRobie-Belle DJ, Wrighton SA (2000). Present and future in vitro approaches for drug metabolism. J Pharmacol Toxicol Methods 44: 313-324.
43. Ferslew KE, Hagardorn AN, Harlan GC, McCormick WJ (1998). A fatal drug interaction between clozapine and fluoxetine. J Forensic Sci 43: 1082-1085.
44. Fleishaker JC, Hulst LK (1994). A pharmacokinetic and pharmacodynamic evaluation of the combined administration of alprazolam and fluvoxamine. Eur J Clin Pharmacol 46: 35-39.
45. Fogelman SM, Schmider J, Venkatakrishnan K, von Moltke LL, Harmatz JS, Shader RI et al (1999). O- and N-demethylation of venlafaxine in vitro by human liver microsomes and by microsomes from cDNA-transfected cells: effect of metabolic inhibitors and SSRI antidepressants. Neuropsychopharmacology 20: 480-490.
46. Food and Drug Administration (2000). Briefing Document for Zeldox Capsules. 19 July 2000. FDA Psychopharmacological Drugs Advisory Committee.
47. Food and Drug Administration. MedWatch (2004). The FDA Safety Information and Adverse Event Reporting Program 2004. (Internet: www.fda.gov/medwatch).
48. Fuller RW, Perry KW (1989). Effect of fluoxetine pretreatment on plasma and tissue concentrations of desipramine in rats. Res Commun Chem Pathol Pharmacol 66: 375-384.
49. Gandhi TJ, Weingart SN, Borus J, Seger AC, Peterson J, Burdick E et al (2003). Adverse drug events in ambulatory care. N Engl J Med 358: 1556-1564.
50. Gibaldi M, Perrier D (1982). Pharmacokinetics, 2nd revised and expanded. Marcel Dekker Inc.: New York.
51. GlaxoSmithKline (2003). Research Triangle Park, NC, Wellbutrin (bupropion HCl) [package insert].
52. Gonzalez FJ (1992). Human cytochromes P450: problems and prospects. Trends Pharmacol Sci 13: 346-352.
53. Gonzalez FJ, Idle JR (1994). Pharmacogenetic phenotyping and genotyping. Present status and future potential. Clin Pharmacokinet 26: 59-70.
54. Goodnick PJ (1989). Influence of fluoxetine on plasma levels of desipramine. Am J Psychiatry 146: 552.
55. Gram LF (1975). Effects of perphenazine on imipramine metabolism in man. Psychopharmacol Commun 1: 165-175.
56. Gram LE, Overø KF (1972). Drug interaction: inhibitory effect of neuroleptics on metabolism of tricyclic antidepressants in man. BMJ 1: 463-465.
57. Gram LE, Overø KF, Kirk L (1974). Influence of neuroleptics and benzodiazepines on metabolism of tricyclic antidepressants in man. Am J Psychiatry 131: 863-866.
58. Green DS, Salazar DE, Dockens RC, Kroboth P, Barbhaiya RH (1995). Coadministration of nefazodone with benzodiazepines, III: a pharmacokinetic interaction study with alprazolam. J Clin Psychopharmacol 15: 399-408.
59. Greenblatt DJ, Abernathy DR, Morse DS, Harmatz JS, Shodes RI (1984). Clinical importance of the interaction of diazepam and cimetidine. N Engl J Med 318: 1639-1643.
60. Greenblatt DJ, Preskorn SH, Cotreau MM, Horst WD, Harmatz JS (1992). Fluoxetine impairs clearance of alprazolam but not of clonazepam. Clin Pharmacol Ther 52: 479-486.
61. Greenblatt DJ, Sellers EM, Koch-Weser J (1982). Importance of protein binding for the interpretation of serum or plasma drug concentrations. J Clin Pharmacol 22: 259-263.
62. Grimsley SR, Jann MW, Carter JG, D'Mello AP, D'Souza MJ (1991). Increased carbamazepine plasma concentrations after fluoxetine coadministration. Clin Pharmacol Ther 50: 10-15.
63. Grygiel JJ, Birkett DJ (1981). Cigarette smoking and theophylline clearance and metabolism. Clin Pharmacol Ther 30: 491-496.
64. Guengerich FP (1997). Role of cytochrome P450 enzymes in drug-drug interactions. Adv Pharmacol 43: 7-35.
65. Guzey C, Norstrom A, Spigset O (2002). Change from the CYP2D6 extensive metabolizer to the poor metabolizer phenotype during treatment with bupropion. Ther Drug Monit 24: 436-437.
66. Harrison WM, McGrath PJ, Stewart JW, Quitkin F (1990). MAOIs and hypertensive crises: the role of OTC drugs. J Clin Psyuchiatry 51: 212-213.
67. Hemeryck A, DeVriendt C, Belpaire FM (2000). Effect of selective serotonin reuptake inhibitors on the oxidative metabolism of propafenone: in vitro studies using human liver microsomes. J Clin Psychopharmacol 20: 428-434.
68. Henry JA, Alexander CA, Sener EK (1995). Relative mortality from overdose of antidepressants. BMJ 310: 221-224.
69. Hesse LM, Venkatakrishnan K, Court MH et al (2000). CYP2B6 mediates the in vitro hydroxylation of bupropion: potential drug interactions with other antidepressants. Drug Metab Dispos 28: 1176-1183.
70. Houston JB (1994). Utility of in vitro drug metabolism data in predicting in vivo metabolic clearance. Biochem Pharmacol 47: 1469-1479.
71. Ito K, Brown HS, Houston JB (2004). Database analyses for the prediction of in vivo drug-drug interactions from in vitro data. Br J Clin Pharmacol 57: 473-486.
72. Ito K, Hallifax D, Obach RS, Houston JB (2005). Impact of parallel pathways of drug elimination and multiple cytochrome P450 involvement on drug-drug interactions: CYP2D6 paradigm. Drug Metab Dispos 33: 837-844.
73. Jeppesen U, Gram LF, Vistisen K, Loft S, Poulsen HE, Brøsen K (1996a). Dose-dependent inhibition of CYP1A2, CYP2C19 and CYP2D6 by citalopram, fluoxetine, fluvoxamine and paroxetine. Eur J Clin Pharmacol 51: 73-78.
74. Jeppesen U, Loft S, Poulsen HE, Brsen K (1996b). A fluvoxamine-caffeine interaction study. Pharmacogenetics 6: 213-222.
75. Juntti-Patinen L, Neuvonen PJ (2002). Drug-related deaths in a university central hospital. Eur J Clin Pharmacol 58: 479-482.
76. Jurima-Romet M, Wright M, Neigh S (1998). Terfenadine-antidepressant interactions: an in vitro inhibition study using human liver microsomes. Br J Clin Pharmacol 45: 318-321.
77. Juurlink DN, Mamdani M, Kopp A, Laupacis A, Redelmeier DA (2003). Drug-drug interactions among elderly patients hospitalized for drug toxicity. JAMA 289: 1652-1658.
78. Kahn D, Silver JM, Opler LA (1989). The safety of switching rapidly from tricyclic antidepressants to monoamine oxidase inhibitors. J Clin Psychopharmacol 9: 198-202.
79. Kakkar T, Boxenbaum H, Mayersohn M (1999). Estimation of Ki in a competitive enzyme-inhibition model: comparisons among three methods of data analysis. Drug Metab Dispos 27: 756-762.
80. Kivisto KT, Neuvonen PJ, Klotz U (1994). Inhibition of terfenadine metabolism pharmacokinnetics and pharmacodynamic consequences. Clin Pharmacokinet 27: 1-5.
81. Kobayashi K, Yamamoto T, Chiba K, Tani M, Ishizaki T, Kuroiwa Y et al (1995). The effects of selective serotonin reuptake inhibitors and their metabolites on s-mephenytoin 4-hydroxylase activity in human liver microsomes. Br J Clin Pharmacol 40: 481-485.
82. Kotlyar M, Brauer LH, Tracy TS, Hatsukami DK, Harris J, Bronars CA et al (2005). Inhibition of CYP2D6 activity by bupropion. J Clin Psychopharmacol 25: 226-229.
83. Krenzelok EP (2000). Sildenafil: clinical toxicology profile. J Toxicol Clin Toxicol 38: 645-651.
84. Kurtz DL, Bergstrom RF, Goldberg MJ, Cerimele BJ (1997). The effect of sertraline on the pharmacokinetics of desipramine and imipramine. Clin Pharmacol Ther 62: 145-156.
85. Lane RM (1996). Pharmacokinetic drug interaction potential of selective serotonin reuptake inhibitors. Int Clin Psychopharmacol 11(Suppl 5): 31-61.
86. Lasher TA, Fleishaker JC, Steenwyk RC, Antal EJ (1991). Pharmacokinetic pharmacodynamic evaluation of the combined administration of alprazolam and fluoxetine. Psychopharmacology 104: 323-327.
87. Lazarou U, Pomeranz BH, Corey PN (1998). Incidence of adverse drug reactions in hospitalized patients: a meta-analysis of prospective studies. JAMA 270: 1200-1205.
88. Lemberger L, Rowe H, Bosomworth JC, Tenbarge JB, Bergstrom RF (1988). The effect of fluoxetine on the pharmacokinetics and psychomotor responses of diazepam. Clin Pharmacol Ther 43: 412-419.
89. Lin JH, Lu AY (1998). Inhibition and induction of cytochrome P450 and the clinical implications. Clin Pharmacokinet 35: 361-390.
90. Lin Y, Lu P, Tang C, Mei Q, Sandig G, Rodrigues AD et al (2001). Substrate inhibition kinetics for cytochrome P450-catalyzed reactions. Drug Metab Dispos 29: 368-374.
91. Liston HL, DeVane CL, Boulton DW, Risch SC, Markowitz JS, Goldman J (2002). Differential time course of cytochrome P450 2D6 enzyme inhibition by fluoxetine, sertraline, and paroxetine in healthy volunteers. J Clin Psychopharmacol 22: 169-173.
92. Liston HL, Markowitz JS, DeVane CL (2001). Drug glucuronidation in clinical psychopharmacology. J Clin Psychopharmacol 21: 500-515.
93. Markowitz J, DeVane CL (1997). The drug interaction potential of fluoxetine, sertraline, and paroxetine in four state psychiatric hospitals. Ther Drug Monit 19: 244-245.
94. Markowitz JS, Gill HS, Lavia M, Brewerton TD, DeVane CL (1996). Fluvoxamine-clozapine dose dependent interaction. Can J Psychiatry 41: 670-671.
95. Meyer UA, Zanger UM, Grant D et al (1990). Genetic polymorphisms of drug metabolism. Adv Drug Res 19: 197-241.
96. Mitchell JR, Horning MG (eds) (1987). Drug Metabolism and Drug Toxicity. Raven Press: New York.
97. Monahan BP, Ferguson CL, Killeavy ES, Lloyd BK, Troy J, Cantilena Jr LR (1990). Torsades de pointes occurring in association with terfenadine use. JAMA 264: 2788-2790.
98. Moore N, Lecointre D, Noblet C, Mabille M (1998). Frequency and cost of serious adverse drug reactions in a department of general medicine. Br J Clin Pharmacol 45: 301-308.
99. National Institute for Health Care Management (2002). Internet www.nihcm.org/spending2001.pdf Prescription Drug Expenditures in 2001, May 6, 2002, pp 1-19.
100. Neal JM, Kunze KL, Levy RH, O'Reilly RA, Trager WF (2003). KiIV, an in vivo parameter for predicting the magnitude of a drug interaction arising from competitive enzyme inhibition. Drug Metab Dispos 31: 1043-1048.
101. Nielsen KK, Flinois JP, Beaune P, Brosen K (1996). The biotransformation of clomipramine in vitro, identification of the cytochrome P450s responsible for the separate metabolic pathways. J Pharmacol Exp Ther 277: 1659-1664.
102. Nelson JC, Jatlow PI (1980). Neuroleptic effect on desipramine steady-state plasma concentrations. Am J Psychiatry 137: 1232-1234.
103. Nelson JC, Mazure CM, Bowers MB, Jatlow PI (1991). A preliminary, open study of the combination of fluoxetine and desipramine for rapid treatment of major depression. Arch Gen Psychiatry 48: 303-307.
104. Nemeroff CB, DeVane CL, Pollock BG (1996). Antidepressants and the cytochrome P450 system. Am J Psychiatry 153: 311-320.
105. Obach RS (1996). The importance of nonspecific binding in in vitro matrices, its impact on enzyme kinetic studies of drug metabolism reactions, and implications for in vitro-in vivo correlations. Drug Metab Dispos 24: 1047-1049.
106. Obach RS (1997). Nonspecific binding to microsomes: impact on scale-up of in vitro intrinsic clearance to hepatic clearance as assessed through examination of warfarin, imipramine, and propranolol. Drug Metab Dispos 25: 1359-1369.
107. Obach RS (1999). Prediction of human clearance of twenty-nine drugs from hepatic microsomal intrinsic clearance data: an examination of in vitro half-life approach and non-specific binding to microsomes. Drug Metab Dispos 27: 1350-1359.
108. Olesen OV, Linnet K (2000). Fluvoxamine-clozapine drug interaction: inhibition in vitro of five cytochrome P450 isoforms involved in clozapine metabolism. J Clin Psychopharmacol 20: 35-42.
109. Otton SV, Ball SE, Cheung SW, Inaba T, Sellers EM (1994). Comparative inhibition of the polymorphic enzyme CYP2D6 by venlafaxine and other 5HT uptake inhibitors. Clin Pharmacol Ther 55: 141.
110. Otton SV, Wu D, Joffe RT, Cheung SW, Sellers EM (1993). Inhibition by fluoxetine of cytochrome P450 2D6 activity. Clin Pharmacol Ther 53: 401-409.
111. Paine MF, Ludington SS, Chen M-L, Stewart PW, Shiew-Mei H, Watkins PB (2005). Do men and women differ in proximal small intestinal CYP3A or P-glycoprotein expression? Drug Metab Dispos 33: 426-433.
112. Pelkonen O, Maenpaa J, Taavitsainen P, Rautio A, Raunio H (1998). Inhibition and induction of cytochrome P450 enzymes. Xenobiotica 28: 1203-1253.
113. Perucca E, Gatti G, Cipolla G, Spina E, Barel S, Soback S et al (1994). Inhibition of diazepam metabolism by fluvoxamine: a pharmacokinetic study in norml volunteers. Clin Pharmacol Ther 56: 471-476.
114. Pollock BG, Sweet RA, Kirshner M, Reynolds III CF (1996). Bupropion plasma levels and CYP2D6 phenotype. Ther Drug Monit 18: 581-585.
115. Preskorn SH, Alderman J, Chung M, Harrison W, Messig M, Harris S et al (1994). Pharmacokinetics of desipramine coadministered with sertraline or fluoxetine. J Clin Psychopharmacol 14: 90-98.
116. Preskorn SH, Baker B (1997). Fatality associated with combined fluoxetine-amitriptyline therapy. JAMA 277: 1682.
117. Preskorn SH, Beber JH, Faul JC, Hirshfeld RMA (1990). Serious adverse effects of combining fluoxetine and tricyclic antidepressants. Am J Psychiatry 147: 532.
118. Rasmussen BB, Maenpaa J, Pelkonen O, Loft S, Poulsen HE, Lykkesfeldt J et al (1995). Selective serotonin reuptake inhibitors and theophylline metabolism in human liver microsomes: potent inhibition by fluvoxamine. Br J Clin Pharmacol 39: 151-159.
119. Rasmussen BB, Neilsen TL, Brosen K (1998). Fluvoxamine is a potent inhibitor of the metabolism of caffeine in vitro. Pharmacol Toxicol 83: 240-245.
120. Ray WA (2003). Population-based studies of adverse drug effects. N Engl J Med 349: 1592-1594.
121. Rochat B, Baumann P, Andus KL (1999). Transport mechanisms for the antidepressant citalopram in brain microvessel endothelium. Brain Res 831: 229-236.
122. Rolan PE (1994). Plasma protein binding displacement interactions - why are they still regarded as clinically important? Br J Clin Pharmacol 37: 125-128.
123. Rowland M, Matin SB (1973). Kinetics of drug-drug interactions. J Pharmacokinet Biopharm 1: 553-567.
124. Sallee FR, DeVane CL, Ferrell RE (2000). Fluoxetine related death in a child with cytochrome P450 2D6 deficiency. J Child Adolesc Psychopharmacol 10: 27-34.
125. Sansom LN, Evans AM (1996). What is the true clinical significance of plasma protein binding displacement interactions? Drug Safety 12: 223-227.
126. Schmid B, Bircher J, Preisig R, Kupfer A (1985). Polymorphic dextromethorphan metabolism: co-segregation of oxidative O-demethylation with debrisoquine hydroxylation. Clin Pharmacol Ther 38: 618-624.
127. Schmider J, Greenblatt DJ, von Moltk LL, Harmatz JS, Shader RI (1996a). Inhibition of cytochrome P450 by nefazodone in vitro: studies of dextromethorphan O- and N-demethylation. Br J Clin Pharmacol 41: 339-343.
128. Schmider J, Greenblatt DJ, von Moltke LL, Shader RI (1996b). Relationship of in vitro data on drug metabolism to in vivo pharmacokinetics and drug interactions: implications for diazepam disposition in humans. J Clin Psychopharmacol 16: 267-272.
129. Sellers EM (1979). Plasma protein displacement interactions are rarely of clinical significance. Pharmacology 18: 225-227.
130. Shad MU, Preskorn SH (1997). A possible bupropion and imipramine interaction. J Clin Psychopharmacol 17: 118-119.
131. Shader RI, Greenblatt DJ, von Moltke LL (1994). Fluoxetine inhibition of phenytoin metabolism. J Clin Psychopharmacol 14: 375-376.
132. Shader RI, von Moltke LL, Schmider J, Harmatz JS, Greenblatt DJ (1996). The clinician and drug interactions - an update. J Clin Psychopharmacol 16: 197-201.
133. Skjelbo E, Brøsen K (1992). Inhibitors of imipramine metabolism by human liver microsomes. Br J Clin Pharmacol 34: 256-261.
134. Sotaniemi EA, Arranto AJ, Pelkonen O, Pasanen M (1997). Age and cytochrome P450-linded drug metabolin humans: an analysis of 226 subjects with equal histopathologic conditions. Clin Tharmacol Ther 61: 331-339.
135. Spigset O (1999). Adverse reactions of selective serotonin reuptake inhibitors: reports from a spontaneous reporting system. Drug Safety 20: 277-287.
136. Sproule BA, Otton SV, Cheung SW, Zhong XH, Romach MK, Sellers EM (1997). CYP2D6 inhibition in patients treated with sertraline. J Clin Psychopharmacol 17: 102-106.
137. Störmer E, Von Moltke LL, Shader RI, Greenblatt DJ (2000). Metabolism of the antidepressant mirtazapine in vitro: contribution of cytochromes P-450 1A2, 2D6, and 3A4. Drug Metab Dispos 28: 1168-1175.
138. Testa B, Jenner P (1976). Drug Metabolism Chemical and Biochemical Aspects. Marcel Kekker Inc.: New York.
139. Tran TH, von Moltke LL, Venkatakrishnan K, Granda BW, Gibbs MA, Obach RS et al (2002). Microsomal protein concentration modifies the apparent inhibitory of CYP3A inhibitors. Drug Metab Dispos 30: 1441-1445.
140. Uhr M, Grauer MT, Holsboer F (2003). Differential enhancement of antidepressant penetration into the brain in mice with abvblab (mrd1ab) P-glycoprotein gene disruption. Biol Psychiatry 15: 840-846.
141. Uhr M, Steckler T, Yassouridis A, Holsboer F (2000). Penetration of amitriptyline, but not of fluoxetine, into brain is enhanced in mice with blood-brain barrier deficiency due to mdrla P-glycoprotein gene disruption. Neuropsychopharmacology 22: 380-387.
142. Vandel S, Bertschy G, Bonin G, Neselof S, Francois TH, Vandel B et al (1992). Tricyclic antidepressant plasma levels after fluoxetine addition. Neuropsychobiology 25: 202-207.
143. Vaughan DA (1988). Interaction of fluoxetine with tricyclic antidepressants. Am J Psychiatry 145: 1478.
144. Venkatakrishnan K, non Moltke LL, Obach RS, Greenblatt DJ (2003). Drug metabolism and drug interactions: application and clinical value of in vitro models. Curr Drug Metab 4: 423-459.
145. von Moltke L, Greenblatt DJ, Shader RI (1992). In vitro inhibition of alprazolam oxidation by fluoxetine and norfluoxetine. J Clin Pharmacol 32: 764 (Abstract).
146. von Moltke LL, Greenblatt DJ, Cotreau-Bibbo MM, Duan SX, Harmatz JS, Shader RI (1994). Inhibition of desipramine hydroxylation in vitro by serotonin-reuptake inhibitor antidepressants, and by quinidine and ketoconazole: a model system to predict drug interactions in vivo. J Pharm Exp Ther 268: 1278-1283.
147. von Moltke LL, Greenblatt DJ, Court MH, Duzn SX, Harmatz JS, Shader RI (1995). Inhibition of alprazolam and desipramine hydroxylation in vitro by paroxetine and fluvoxamine: comparison with other selective serotonin reuptake inhibitor antidepressants. J Clin Psychopharmacol 15: 125-131.
148. von Moltke LL, Greenblat DJ, Duan SX, Schmider J, Kudchadker L, Fogelman SM et al (1996). Phenacetin O-deethylation by human liver microsomes in vitro: inhibition by chemical probes, SSRI antidepressants, nefazodone and venlafaxine. Psychopharmacology 128: 398-407.
149. von Moltke LL, Greenblatt DJ, Schmider J, Wright CE, Harmatz JS, Shader RI et al (1998). In vitro approaches to predicting drug interactions in vivo. Biochem Pharmacol 55: 113-122.
150. Wagner W, Plekkenpol B, Gray TE, Vlaskamp H, Essers H (1992). Review of fluvoxamine safety database. Drugs 43(Suppl 2): 48-54.
151. Wagner W, Zaborny BA, Gray TE (1994). Fluvoxamine. A review of its safety profile in world-wide studies. Int Clin Psychopharmacol 9: 223-227.
152. Wang J-S (2001). In vivo and in vitro studies on drug metabolism and interactions involving mibefradil, isradipine, lidocaine, selegiline and metronidazole. University of Helsinki Academic Dissertation, pp 1-65.
153. Wang RW, Newton DJ, Liu N, Atkins WM, Lu AY (2000). Human cytochrome P-450 3A4: in vitro drug-drug interaction patterns are substrate-dependent. Drug Metab Dispos 28: 360-366.
154. Weilburg JB, Rosenbaum JF, Biederman J, Sachs GS, Pollack MH, Kelly K (1989). Fluoxetine added to non-MAOI antidepressants converts nonresponders to responders: a preliminary report. J Clin Psychiatry 50: 447-449.
155. Weiss J, Dormann S-MG, Martin-Facklam M, Kerpen CJ, Ketabi-Kiyanvash N, Haefeli WE (2003). Inhibition of P-glycoprotein by newer antidepressants. J Pharm Exp Ther 305: 197-204.
156. Winkinson GR, Shand DG (1975). A physiological approach to hepatic drug clearance. Clin Pharmacol Ther 18: 377-390.
157. Wolbold R, Klein K, Burk O et al (2003). Sex is a major determinant of CYP3A4 expression in human liver. Hepatology 38: 978-988.
158. Wright CE, Lasher-Sisson TA, Steenwyk RC, Swanson CN (1992). A pharmacokinetic evaluation of the combined administration of triazolam and fluoxetine. Pharmacotherapy 12: 103-106.
159. Yuan R, Parmelee T, Balian JD, Uppoor RS et al (1999). In vitro metabolic interaction studies: experience of the Food and Drug Administration. Clin Pharmacol Ther 66: 9-15.
160. Yuan R, Madani S, Xiao-Xiong W, Reynolds K, Huang S-M (2002). Evaluation of cytochrome P450 probe substrates commonly used by the pharmaceutical industry to study in vitro drug interactions. Drug Metab Dispos 30: 1311-1319.
161. Zussman BD, Davie CC, Fowles SE, Duman R, Lang U, Wargenau M et al (1995). Sertraline, like other SSRIs, is a significant inhibitor of desipramine metabolism in vivo. Br J Clin Pharmacol 39: 550-551.